- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Oct 4, 2022
Finance
Oct. 3 Quick Takes: Myovant open to sweeter Sumitovant proposal
Plus Alloy raises series D and updates from Omeros, NeuShen
BioCentury | Dec 3, 2021
Product Development
Dec. 2 Quick Takes: $109M series C for Acepodia
Plus Tune catches $40M series A from NEA, Emerson, and Astellas-Dyno, Omeros, Vir and more
BioCentury | Oct 30, 2020
Distillery Therapeutics
Targeting water channel AQP1 for hypertrophic cardiomyopathy
DISEASE CATEGORY: Cardiovascular
INDICATION: Cardiomyopathy Inhibiting AQP1, a water channel expressed in cardiac and vascular tissues, could treat hypertrophic cardiomyopathy. Among 26
INDICATION: Cardiomyopathy Inhibiting AQP1, a water channel expressed in cardiac and vascular tissues, could treat hypertrophic cardiomyopathy. Among 26
BioCentury | Feb 1, 2019
Clinical News
Eyenovia planning NDA in 1Q20 for microdose ophthalmic solution to induce mydriasis
Items per page:
1 - 10 of 61